Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Cephalalgia ; 42(13): 1317-1322, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-35702033

RESUMEN

BACKGROUND: Alternative metrics to traditional, citation-based metrics are increasingly being used. These are complementary to traditional metrics, like downloads and citations, and give information on how often a given journal article is discussed and used in professional (reference managers) and social networks, such as mainstream media and Twitter. Altmetrics is used in most journals and is available in all indexed headache medicine journals. Whether Altmetrics have an input on traditional, citation-based metrics or whether it is a stand-alone metric system is not clear. Actively promoting a paper through media channels will probably increase the Altmetric score but the question arises whether this will also increase citations and downloads of this individual paper. METHODS: Focusing on this point we performed a randomized study in order to test the hypothesis that a promotion intervention would improve citations and other science metric scores. We selected 48 papers published in Cephalalgia from July 2019 to January 2020 and randomized them to either receive an active promotion through social media channels or not. The primary outcome used was the difference between mean article citations with versus without intervention 12 months after the intervention period. RESULTS: The results show that the alternative metrics significantly increased for those papers randomly selected to receive an intervention compared to those who did not. This effect was observed in the first 12 months, right after the boosting strategy was performed. The higher promoted paper diffusion in social media lead to a significantly higher number of citations and downloads. CONCLUSION: Further promotion strategies should be studied in order to tailor the best cost-benefit intervention.


Asunto(s)
Factor de Impacto de la Revista , Medios de Comunicación Sociales , Humanos , Bibliometría , Red Social
2.
Cephalalgia ; 40(6): 597-605, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31757169

RESUMEN

BACKGROUND: Disability imposed by headache disorders constitutes an expressive economic burden, mostly from indirect costs due to absenteeism and presenteeism. OBJECTIVE: To estimate indirect costs from absenteeism and presenteeism due to headache disorders in Brazil. METHODS: In a secondary, descriptive analysis of two nationwide databases, we estimated indirect costs based on headache-related disability and socioeconomic data. RESULTS: In the first database analyzed (n = 3838), 12.8% of the employed population with headache disorders missed at least 1 day of work in the last 3 months (mean, 95% CI = 4.2 days [3.7-4.6]). Based on the prevalence of headache disorders, days lost due to headaches and income data, R$ 40.4 billion (Int$ 20 billion) are lost due to headache-related absenteeism annually. For presenteeism, 26.2% of the employed population with headache disorders worked at least 1 day in the last 3 months with 50% reduced productivity (mean, 95% CI = 5.7 days [5.3-6.2]), amounting to R$ 27.3 billion (Int$ 13.5 billion) of financial loss annually. In the other database analysed (n = 205,546), 14,052 (6.8%) respondents missed work/school or household duties in the past 2 weeks due to some disease. Of these, 4.7% attributed their days lost to headaches disorders in the economically active population, which ranked 4th as main cause of days lost due to disease, among 23 common diseases. CONCLUSIONS: The economic burden of headache disorders in Brazil, mostly due to migraine (55.4%), may cost up to R$ 67.6 billion (Int$ 33.5 billion) annually, and headache disorders represent a leading cause of absenteeism due to disease.


Asunto(s)
Costo de Enfermedad , Cefalea/economía , Absentismo , Brasil , Evaluación de la Discapacidad , Humanos , Presentismo
3.
Cephalalgia ; 39(13): 1700-1709, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31370669

RESUMEN

PURPOSE: The pineal gland plays an important role in biological rhythms, circadian and circannual variations, which are key aspects in several headache disorders. OVERVIEW: Melatonin, the main pineal secreting hormone, has been extensively studied in primary and secondary headache disorders. Altered melatonin secretion occurs in many headache syndromes. Experimental data show pineal gland and melatonin both interfere in headache animal models, decreasing trigeminal activation. Melatonin has been shown to regulate CGRP and control its release. DISCUSSION: Melatonin has been used successfully as a treatment for migraine, cluster headaches and other headaches. There is a rationale for including the pineal gland as a relevant brain structure in the mechanisms of headache pathophysiology, and melatonin as a treatment option in primary headache.


Asunto(s)
Cefalea/fisiopatología , Glándula Pineal/fisiopatología , Adulto , Animales , Péptido Relacionado con Gen de Calcitonina/fisiología , Estudios de Casos y Controles , Niño , Ritmo Circadiano/fisiología , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Método Doble Ciego , Cefalea/diagnóstico por imagen , Cefalea/tratamiento farmacológico , Cefalea/patología , Humanos , Melatonina/fisiología , Melatonina/uso terapéutico , Oxidación-Reducción , Núcleo Hipotalámico Paraventricular/fisiopatología , Glándula Pineal/metabolismo , Glándula Pineal/patología , Receptores de Melatonina/agonistas , Receptores de Melatonina/fisiología , Serotonina/metabolismo , Ganglio Cervical Superior/fisiopatología
5.
Cephalalgia ; 34(6): 464-72, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24326236

RESUMEN

BACKGROUND: High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex (rTMS-DLPFC) is an effective treatment for depression. Preliminary studies indicated beneficial effects of rTMS-DLPFC on pain relief in patients treated for depression, and in patients with chronic migraine. METHODS: In this randomized, double-blind, parallel-group, single-center, proof-of-principle clinical trial, we tested the hypothesis that 23 sessions of active rTMS-DLPFC delivered over eight weeks would be feasible, safe and superior to sham rTMS to decrease the number of headache days in 18 patients with chronic migraine without severe depression. Per-protocol analysis was performed. RESULTS: rTMS-DLPFC applied over eight weeks was feasible and safe in patients with chronic migraine. Contrary to our primary hypothesis, the number of headache days decreased significantly more in the sham group than in the group treated with active rTMS-DLPFC at eight weeks. Average decrease in headache days was >50% in the sham group, indicating a powerful placebo response. Pain intensity improved in both groups to a similar extent. CONCLUSIONS: Positive results of M1 stimulation in other studies, and the absence of significant benefits of active high-frequency rTMS of the DLPFC in the present study, point to M1 as a more promising target than the DLPFC, for larger trials of noninvasive brain stimulation in patients with chronic migraine.


Asunto(s)
Trastornos Migrañosos/terapia , Estimulación Magnética Transcraneal/métodos , Adulto , Método Doble Ciego , Estudios de Factibilidad , Femenino , Humanos , Masculino , Trastornos Migrañosos/fisiopatología , Corteza Prefrontal/fisiopatología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA